Von Willebrand Disease is often treated as a “mild” bleeding disorder, yet major bleeding has been reported in about 29% over a lifetime. Even stranger, many people have normal factor VIII levels, and up to 75% remain undiagnosed. From a 0.60 to 1.30% estimated prevalence range to type 2M making up around 15% of cases in some cohorts, the picture is far more uneven than most screening cutoffs suggest.
Key Takeaways
- VWD is associated with variable factor VIII (FVIII) levels; in many cases of mild VWD, FVIII is normal.
- Type 2M VWD is reported to account for about 15% of VWD cases in some cohorts.
- Up to 75% of people with VWD are undiagnosed.
- The lifetime incidence of major bleeding in VWD is reported as about 29%.
- A 2016 systematic review reported an estimated prevalence range for VWD of 0.60 to 1.30%.
- In the International Society on Thrombosis and Haemostasis (ISTH) VWD bleeding assessment tools literature, the International Society on Thrombosis and Haemostasis (ISTH) BAT was designed to quantify mucocutaneous and other bleeding scores across life
- The ISTH-BAT (ISTH Bleeding Assessment Tool) was introduced in 2010 and provides a standardized scoring system for bleeding severity in inherited bleeding disorders
- For VWD, the World Federation of Hemophilia (WFH) notes that mild disease can still involve clinically significant bleeding
- WHO estimates that tranexamic acid reduces bleeding during menstruation and procedures in bleeding disorders (including VWD), per WHO drug guidance
- Per WFH guidance, desmopressin response should be assessed (DDAVP trial) in patients where DDAVP use is being considered
- A 2019 international consensus framework recommends using VWF activity (VWF:RCo or VWF:GPI) and VWF antigen (VWF:Ag) to support VWD diagnosis and classification
- The global market for hemophilia and rare bleeding disorder therapeutics (including VWD products) was estimated at $18.2 billion in 2023 (industry market estimate)
- In 2024, the US hemophilia/VWD treatment market was estimated at $9.6 billion (industry forecast)
- The global von Willebrand disease therapeutics market was forecast to reach $2.9 billion by 2030 (industry forecast)
- $12,900 per patient per year was estimated direct medical cost for severe VWD in the same economic analysis (analysis estimate)
Up to 75% of people with von Willebrand disease are undiagnosed, and about 29% experience major bleeding.
Related reading
01 · Category
Clinical Subtypes2 stats
01
VWD is associated with variable factor VIII (FVIII) levels; in many cases of mild VWD, FVIII is normal.
02
Type 2M VWD is reported to account for about 15% of VWD cases in some cohorts.
Interpretation
Clinical Subtypes Interpretation
Within the clinical subtypes of VWD, mild cases often still have normal FVIII levels, and Type 2M represents about 15% of cases in some cohorts, showing that subtype patterns can span from normal factor profiles to a meaningful distinct share of diagnoses.
02 · Category
Epidemiology9 stats
01
Up to 75% of people with VWD are undiagnosed.
02
The lifetime incidence of major bleeding in VWD is reported as about 29%.
03
A 2016 systematic review reported an estimated prevalence range for VWD of 0.60 to 1.30%.
04
Among people with VWD, mucocutaneous bleeding is the most common bleeding phenotype, reported in about 80% in some cohorts.
05
In a population-based Swedish study, the prevalence of VWD was estimated at 1.3%.
06
In a UK primary care study, the prevalence of diagnosed bleeding disorders consistent with VWD was 3.3 per 10,000.
07
VWD accounts for approximately 1% to 2% of all patients with inherited bleeding disorders seen in hematology clinics.
08
1% of the general population is estimated to have von Willebrand factor (VWF) levels below 30 IU/dL, which is often used as an abnormal threshold in VWD screening
09
Approximately 75% of patients with VWD have a mild bleeding phenotype
Interpretation
Epidemiology Interpretation
Epidemiology data suggest VWD is relatively common yet often missed, with up to 75% of people undiagnosed and prevalence estimates ranging from about 0.60 to 1.30% reported in reviews and roughly 1.3% in Sweden.
More related reading
03 · Category
Clinical Outcomes3 stats
01
In the International Society on Thrombosis and Haemostasis (ISTH) VWD bleeding assessment tools literature, the International Society on Thrombosis and Haemostasis (ISTH) BAT was designed to quantify mucocutaneous and other bleeding scores across life
02
The ISTH-BAT (ISTH Bleeding Assessment Tool) was introduced in 2010 and provides a standardized scoring system for bleeding severity in inherited bleeding disorders
03
For VWD, the World Federation of Hemophilia (WFH) notes that mild disease can still involve clinically significant bleeding
Interpretation
Clinical Outcomes Interpretation
Clinical outcomes in VWD remain clinically meaningful despite mild presentations because the ISTH Bleeding Assessment Tool introduced in 2010 uses standardized scoring to quantify mucocutaneous and other bleeding across life, and the WFH notes that mild disease can still lead to clinically significant bleeding.
04 · Category
Treatment And Guidelines5 stats
01
WHO estimates that tranexamic acid reduces bleeding during menstruation and procedures in bleeding disorders (including VWD), per WHO drug guidance
02
Per WFH guidance, desmopressin response should be assessed (DDAVP trial) in patients where DDAVP use is being considered
03
A 2019 international consensus framework recommends using VWF activity (VWF:RCo or VWF:GPI) and VWF antigen (VWF:Ag) to support VWD diagnosis and classification
04
A 2018 guideline update recommends that VWD diagnosis should integrate bleeding history with laboratory VWF measurements rather than laboratory values alone
05
In a randomized trial context, tranexamic acid is used to reduce heavy menstrual bleeding in patients with bleeding disorders including VWD
Interpretation
Treatment And Guidelines Interpretation
Treatment and guidelines for Von Willebrand Disease increasingly emphasize evidence based bleeding control and diagnosis, with WHO noting tranexamic acid reduces menstrual bleeding and procedures and multiple VWD guidance updates calling for lab supported assessment such as DDAVP response testing and integrating VWF measurements with bleeding history.
More related reading
05 · Category
Market And Access4 stats
01
The global market for hemophilia and rare bleeding disorder therapeutics (including VWD products) was estimated at $18.2 billion in 2023 (industry market estimate)
02
In 2024, the US hemophilia/VWD treatment market was estimated at $9.6 billion (industry forecast)
03
The global von Willebrand disease therapeutics market was forecast to reach $2.9 billion by 2030 (industry forecast)
04
In a 2023 payer/provider survey, 41% of clinicians reported delays in obtaining VWD-specific therapies as a barrier to care (survey of bleeding disorder centers)
Interpretation
Market And Access Interpretation
Market and access pressures are becoming a real constraint as the global VWD therapeutics market is forecast to climb to $2.9 billion by 2030 while 41% of clinicians still report delays in obtaining VWD-specific therapies, and US demand alone is projected to reach $9.6 billion in 2024.
06 · Category
Economic Burden4 stats
01
$12,900per patient per year was estimated direct medical cost for severe VWD in the same economic analysis (analysis estimate)
02
A US indirect cost model estimated productivity losses attributable to inherited bleeding disorders including VWD at $1.5 billion annually (model estimate)
03
In the same EQ-5D study, VWD participants reported a mean pain/discomfort problem prevalence of 43% (study reported proportion)
04
In a US survey of women with heavy menstrual bleeding, 13% of those with suspected bleeding disorders were diagnosed with VWD (registry/clinic dataset estimate)
Interpretation
Economic Burden Interpretation
From an economic burden perspective, severe VWD was estimated to cost $12,900 per patient each year in direct medical expenses while broader indirect productivity losses from inherited bleeding disorders were about $1.5 billion annually, showing that both healthcare costs and lost work time can add up substantially even as reported patient-level impact such as 43% experiencing pain/discomfort is also high.
More related reading
07 · Category
Treatment Patterns2 stats
01
In a clinical review of VWD management, DDAVP is generally recommended for mild types only in responsive patients, representing an eligibility proportion of approximately 30–40% of diagnosed VWD patients (eligibility proportion from practice cohorts).
02
Tranexamic acid is recommended as first-line therapy for mucosal bleeding in VWD in multiple guidelines, including typical dosing around 1 g three times daily or 25 mg/kg per dose (recommended dosing amounts in prescribing/guideline documents).
Interpretation
Treatment Patterns Interpretation
In treatment patterns for VWD, only about 30 to 40 percent of diagnosed patients are eligible for DDAVP since it is mainly used for mild responsive cases, while tranexamic acid remains a widely recommended first line option for mucosal bleeding in most guidelines.
08 · Category
Clinical Burden2 stats
01
In VWD cohorts, 22% reported chronic mucocutaneous bleeding symptoms (chronicity proportion).
02
2.5% annual incidence of joint or musculoskeletal bleeding events among individuals with inherited bleeding disorders including VWD (claims-based incidence estimate).
Interpretation
Clinical Burden Interpretation
From a clinical burden perspective, chronic mucocutaneous bleeding affects 22% of people in VWD cohorts, and joint or musculoskeletal bleeding occurs at an estimated 2.5% annual incidence in inherited bleeding disorders including VWD, underscoring a persistent and recurrent symptom load.
More related reading
09 · Category
Market & Access2 stats
01
$2.9 billion forecasted global von Willebrand disease therapeutics market by 2030 (industry forecast value).
02
The United States market included the FDA-approved von Willebrand factor concentrate products that expanded availability over the decade; by 2020, multiple products were available for bleeding episodes (count of commercially available VWD-specific therapies).
Interpretation
Market & Access Interpretation
With a forecast of $2.9 billion in the global von Willebrand disease therapeutics market by 2030 and an expanding set of FDA approved von Willebrand factor concentrate options available for bleeding episodes in the US by 2020, Market and Access appears to be driven by steadily improving product availability that supports future growth.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Von Willebrand Disease Statistics. Gitnux. https://gitnux.org/von-willebrand-disease-statistics
MLA
Lukas Bauer. "Von Willebrand Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/von-willebrand-disease-statistics.
Chicago
Lukas Bauer. 2026. "Von Willebrand Disease Statistics." Gitnux. https://gitnux.org/von-willebrand-disease-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)